Gambro Sale Of U.S. Dialysis Services Leaves $2 Bil. For Possible Acquisitions
This article was originally published in The Gray Sheet
Executive Summary
Gambro's plan to refocus on its core renal and blood bank product offerings by divesting its U.S. dialysis services business provides about $2 bil. for potential acquisitions in related fields
You may also be interested in...
DCA/Medicore Merger Provides Up To $10 Mil. For Dialysis Service Expansion
Dialysis Corporation of America will gain access to capital for dialysis services expansion by acquiring parent company Medicore in a stock-swap valued at $152 mil
DCA/Medicore Merger Provides Up To $10 Mil. For Dialysis Service Expansion
Dialysis Corporation of America will gain access to capital for dialysis services expansion by acquiring parent company Medicore in a stock-swap valued at $152 mil
DaVita investigated by Justice
Dialysis services firm will provide documents relating to medical director compensation, joint venture agreements with physicians and drug services to DoJ under a March 4 subpoena. The U.S. Attorney for the Eastern District of Missouri's investigation "significantly overlaps" with a similar action begun in February 2001 by the U.S. attorney in Philadelphia, the firm notes. DaVita acquisition target Gambro settled similar issues with the St. Louis attorney's office in December 2004 (1"The Gray Sheet" Dec. 13, 2004, p. 12)...